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Scientific Note
Abstract
Uterine leiomyosarcoma (Ut-LMS) develops more frequently in the myometrium of the uterine body than in the uterine cervix. Alt-
hough the development of gynecological tumors is often correlated with the secretion of female hormones that of Ut-LMS does not,
and its risk factor(s) remain unknown. Importantly, a diagnostic biomarker that can distinguish malignant tumor Ut-LMS from be-
nign tumor leiomyoma (LMA), has yet to be established. Therefore, the risk factor(s) associated with Ut-LMS need to be examined
in order to establish a diagnosis and clinical treatment method. Mice with a homozygous deficiency for the proteasome -ring subu-
nit, low-molecular mass polypeptide (LMP)2/1i spontaneously develop Ut-LMS, with a disease prevalence of ~40% by 14 months
of age. In recent studies, we showed that LMP2/1i expression was absent in human Ut-LMS, but present in other human uterine
mesenchymal tumors including uterine LMA. Moreover, LMP2/1i is also known to negatively regulate human Ut-LMS
tumorigenesis. Additional experiments furthermore revealed the differential expression of cyclin E and calponin h1 in human uterine
mesenchymal tumors. Therefore, LMP2/1i is a potential diagnostic biomarker when combined with the candidate molecules, cyclin
E and calponin h1 for human Ut-LMS, and may be a targeted molecule for a new therapeutic approach.
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Scientific Note
Sarcomas are neoplastic malignancies that typically arise in tis-
sues of mesenchymal origin. The identification of novel molecu-
lar mechanisms leading to sarcoma formation and the establish-
ment of new therapies has been hampered by several critical fac-
tors. Human uterine leiomyosarcoma (Ut-LMS) develops more
often in the muscle tissue layer of the uterine body than in the
uterine cervix. The development of gynecologic tumors is often
correlated with female hormone secretion; however, the devel-
opment of human Ut-LMS is not substantially correlated with
hormonal conditions, and the risk factors are not yet known. Im-
portantly, a diagnostic-biomarker which distinguishes malignant
Ut-LMS from benign tumor leiomyoma (LMA) is yet to be estab-
lished. Accordingly, it is necessary to analyze risk factors associ-
ated with human Ut-LMS, to establish novel therapeutic method.
Proteasome -ring subunit LMP2/1i-deficient mice spontane-
ously develop Ut-LMS, with a disease prevalence of ~40% by 14
months of age. We found LMP2/1i expression to be absent in
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Sarcomas are a rare form of malignant tumor with less than
15,000 new cases diagnosed each year in United States. Though
rare, sarcomas are highly debilitating malignancies as they are
often associated with significant morbidity and mortality. Sarco-
mas are biologically very heterogeneous as evidenced by the fact
that these malignant tumors arise from a plethora of different
tissues and cell types. They are classically defined by their tissue
of origin and additionally stratified by their histopathology or
patient’s age at diagnosis. While most tumors of the uterine body
are adenocarcinomas, the uterine cervix tumors are classified into
squamous cancer and adenocarcinoma. Uterine mesenchymal
tumors, which develop in the myometrium have been tradition-
ally divided into benign LMA and malignant Ut-LMS based on
cytological atypia, mitotic activity and other criteria. Ut-LMS is
relatively rare, having an estimated annual incidence of 0.64 per
100,000 women.1 Ut-LMS accounts for 2% ~ 5% of tumors of
the uterine body and develops more often in the muscle layer of
the uterine body than in the uterine cervix. As Ut-LMS is resistant
to chemotherapy and radiotherapy, surgical intervention is virtu-
ally the only means of treatment.2,3 The prognosis for Ut-LMS is
not good, and the five-year survival rate is approximately 35%.
However, developing an efficient adjuvant therapy is expected to
improve the survival rate. Uterine LMA may occur in as many as
70% ~ 80% of women by the age of 50 years.4 Distinguishing
Ut-LMS from other uterine mesenchymal tumors including LMA
is very difficult, and a diagnosis generally requires surgery and
cytoscopy. Diagnostic categories for uterine mesenchymal tumors
and morphological criteria are used to assign cases. The
non-standard subtypes of uterine mesenchymal tumors such as
the epithelioid and myxoid types are classified in a different way
using these features, so the establishment of a diagnostic method
for the identification of non-standard smooth muscle differentia-
tion is important.5,6
High estrogen levels are considered to significantly influence the
development of tumors in the uterine body.7 The mechanisms by
which uterine LMA and Ut-LMS develop are not yet known,
though tumors that have developed in the myometrium for some
reason gradually become larger due to the influence of the female
hormone, estrogen, and generate tumors. However, no correlation
between the development of Ut-LMS and hormonal conditions,
and no obvious risk factors have been found. Although cases
accompanied by hypocalcaemia or eosinophilia have been re-
ported, neither clinical abnormality is an initial risk factor for
Ut-LMS. The identification of a risk factor associated with the
development of Ut-LMS would significantly contribute to the
development of preventive and therapeutic treatments.
Cytoplasmic proteins are mostly degraded by a protease complex,
which has many substrates consisting of twenty-eight 20 to 30
kDa subunits, referred to as the 20S proteasome.8,9 The
proteasomal degradation is essential for many cellular processes,
including the cell cycle, the regulation of gene expression and
immunological function.10 Interferon (IFN)- induces the expres-
sion of large numbers of responsive genes, subunits of protea-
some -ring, i.e., low-molecular mass polypeptide (LMP)2/1i,
LMP7/5i, and LMP10/multicatalytic endopeptidase com-
plex-like (MECL)-1/2i.11 A molecular approach to studying the
correlation of IFN- with tumor cell growth has drawn attention.
Homozygous mice deficient in LMP2/1i show tissue- and sub-
strate-dependent abnormalities in the biological functions of the
proteasome.12 Ut-LMS reportedly occurred in female
LMP2/1i-deficient mice at age 6 months or older, and the inci-
dence at 14 months of age was about 40%.13 Histological studies
of LMP2/1i-lacking uterine tumors have revealed characteristic
abnormalities of Ut-LMS.13 The tumors consisted of uniform
elongated myometrium cells arranged into bundles. The nuclei of
the tumor cells varied in size and shape, furthermore, mitosis was
frequent. In contrast, the myometrium cells of C57BL/6 mice
were normal in appearance. Whereas relatively few
ki-67-positive cells, the proliferating cells of solid tumors, were
observed in the basal cell layer of the normal myometrium, most
of the basal cells vividly expressed ki-67 in LMP2/1i-deficient
mice.13 LMP2/1i-deficient mice that have developed Ut-LMS
undergo considerable weight loss, and then die by 14 months of
age. The LMP2/1i-deficient mice also exhibit skeletal muscle
metastasis from Ut-LMS. Therefore it is likely that LMP2/1i-
deficient mice with Ut-LMS die as a result of the tumor mass and
metastasis.
The non-standard subtypes of uterine mesenchymal tumors such
as the epithelioid and myxoid types are classified in a different
way using these features, so the establishment of a diagnostic
method for the identification of non-standard smooth muscle
differentiation is important.5,6 Pathological studies were per-
formed to demonstrate the validity and reliability of LMP2/1i as
a diagnostic biomarker under the combination of other candidate
molecules, for instance cyclin E and calponin h1, which report-
edly function as anti-oncogenic factor in human Ut-LMS. Patho-
logical examinations revealed a serious loss in the ability to in-
duce LMP2/1i and calponin h1 expressions in human Ut-LMS
tissues in comparison with uterine LMA or normal myometrium
located in the same section, and markedly cyclin E expression in
only human Ut-LMS tissues.14-17 Histological findings were con-
sistent with metastatic Ut-LMS for the skeletal muscle and rec-
tum lesions.14,15 In western blotting and RT-PCR experiments,
LMP2/1i was expressed in normal myometrium, but not in hu-
man Ut-LMS, both strongly supportive of the pathological find-
ings.14,15,17,18 Although we has previously demonstrated that the
abnormal expression of the ovarian steroid receptors, Tp53, ki-67
and mutations of Tp53 were frequently associated with Ut-LMS,
defective LMP2/1i expression appears to be more characteristic
of human Ut-LMS than these factors.15,16
In the case of gynecological cancers, a female hormonal imbal-
ance is often a risk factor for developing tumors.7 As in the case
of uterine LMA, however, a correlation between the development
of Ut-LMS, the female hormone, and hormone receptors has yet
to be elucidated. Recent reports showed the expression of
Lmp2/1i mRNA and protein in luminal and glandular epitheliua,
placenta villi, trophoblastic shells, and arterial endothelial
cells.19-21 These results implicate LMP2/1i in the invasion of
placental villi, degradation of the extracellular matrix, immune
tolerance, glandular secretion, and angiogenesis, but no more
information for sarcomagenesis. Further experiments are also
required to elucidate the molecular mechanism of human
Ut-LMS tumorigenesis involved biological significance of
LMP2/1i; we are investigating the reliability and characteristics
of LMP2/1i as a diagnostic indicator with several clinical re-
search facilities. Histopathologic characteristics of human uterine
human Ut-LMS, but present in human LMA. Therefore, defec-
tive-LMP2/1i expression may be one of the risk factors for hu-
man Ut-LMS. LMP2/1i is a potential diagnostic biomarker for
human Ut-LMS, and may be a targeted-molecule for a new ther-
apeutic approach.
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mesenchymal tumors including mitotically active leiomyoma,
bizarre leiomyoma, lipoleiomyoma, undifferentiated endometrial
sarcoma, epithelioid variant leiomyosarcoma, myxoid variant
leiomyosarcoma, smooth muscle tumors of uncertain malignant
potential (STUMP), leiomyomatoid angiomatous neuroendocrin
tumor (LANT) are summarized.22,23 Clarification of the correla-
tion between these factors and the development of human
Ut-LMS and the identification of specific risk factors may lead to
the development of new clinical treatments for the disease.
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